Novozymes

What Novozymes does

Novozymes A/S, operating as part of Novonesis Group following its 2025 merger with Chr. Hansen, is a Danish biotechnology company headquartered in Bagsværd, Denmark, that designs, produces, and sells industrial enzymes, microbial solutions, and probiotics to business customers across six end markets: bioenergy, food and beverages, household care, human health, industrial bioprocessing, and animal and plant health. Its core technology is biological — proprietary enzyme platforms (including Innova Apex and Innova Turbo introduced in July 2022), microbial strain libraries (notably the BB-12 Bifidobacterium probiotic strain, described as the world's most documented), and fermentation-based production processes. The company has applied AI-driven protein engineering to compress enzyme discovery timelines by an estimated 30–40%, and operates a global direct enterprise sales force plus the now-wholly-owned dsm-firmenich Feed Enzyme Alliance distribution footprint built over more than 25 years.

Novonesis (as the combined entity is branded) sells biological ingredients that customers embed into their own industrial processes — biofuel producers seeking yield improvements, food processors extending shelf life, detergent formulators replacing harsher chemistry, animal nutrition producers reducing antibiotic reliance, and consumer health brands commercializing probiotic supplements. The merger created the world's largest biosolutions company and is reported at a market capitalization of approximately $24.89 billion as of April 2026.

The business model is B2B ingredient supply with enterprise pricing negotiated directly with industrial customers and channel partners across North America, Europe, Asia-Pacific, Latin America, and emerging markets. Revenue mechanics are anchored in volume-based product sales rather than subscription contracts, though long qualification cycles and customer process integration create high revenue stickiness. Recent disclosed financial performance includes Q1 2026 revenue of $1.18B, 7% organic sales growth, a 37.8% adjusted EBITDA margin, and 2026 guidance of 5–7% organic growth with continued margin expansion to 37–38%.

Name

Novozymes

Legal name

Novozymes A/S

Website

https://novozymes.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Novonesis (formerly Novozymes) is a Danish biosolutions company that produces and sells industrial enzymes, microbial solutions, and probiotics to B2B customers across bioenergy, food and beverages, household care, human health, industrial bioprocessing, and animal and plant health worldwide.

Ownership category

akta.pro rank

Product category

Industrial Biotechnology (Biosolutions)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

Keywords

• Industrial enzymes
• Microbial solutions
• Probiotic strains
• Bioenergy biosolutions
• Animal feed enzymes

Headquarters

HQ city

Bagsværd

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Enzyme and Biosolutions Product Sales: Novonesis generates revenue primarily through the sale of industrial enzymes, microbial solutions, and biosolutions across multiple end markets including bioenergy, food & beverages, household care, human health, industrial bioprocessing, and animal & plant health. Revenue is driven by diverse sales across multiple industries and regions.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Novonesis (formerly Novozymes A/S) develops, manufactures, and sells industrial enzymes, microbial solutions, and probiotics (biosolutions) for bioenergy, food & beverages, household care, human health, industrial bioprocessing, and animal & plant health applications. The company sells directly to industrial customers and through strategic channel partnerships, offering proprietary platforms such as Innova Apex, Innova Turbo, and the BB-12 probiotic strain.

Product overview

Novonesis (formerly Novozymes A/S, now part of Novonesis Group following its merger with Chr. Hansen) operates as a biosolutions company offering a unified portfolio of enzymes, microorganisms, and probiotics across six industry verticals: Bioenergy (including Biodiesel, Biogas, Biomass, Carbon capture, Ethanol, and Renewable diesel), Food & Beverages (with enzyme solutions for baking and sensory applications), Household Care (laundry and cleaning enzymes), Human Health (probiotics and postbiotics including the BB-12 strain), Industrial Bioprocessing, and Animal & Plant (feed enzymes, probiotics, and prebiotics for aquaculture and livestock). The company delivers biological solutions that transform industries from agriculture to bioenergy, helping customers produce more from less while reducing environmental impact.

Differentiator

Problem solved

Functional benefit

Brands

• Innova Apex: Enzyme platform introduced July 2022
• Innova Turbo
• BB-12

Products and services

• Bioenergy Biosolutions

Quantifiable outcome

• 7% organic sales growth in Q1 2026
• +4 more outcomes

Named customers1 record

Segments6 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered minor and core.

• UndoAgeminorStrategic or Co-development Partner · 22 June 2026Novozymes signed a Memorandum of Understanding with UndoAge to co-develop probiotics and postbiotics for the Chinese consumer health market. This partnership leverages Novozymes' microbial expertise to enter the emerging Chinese consumer health market with innovative probiotic and postbiotic products.
• dsm-firmenichcoreStrategic or Co-development PartnerNovozymes and dsm-firmenich have worked together for over 25 years on innovating and distributing enzymes for animals as the Feed Enzyme Alliance. Novonesis has now acquired dsm-firmenich's share of the Feed Enzyme Alliance, bringing sales and distribution activities under the same roof as research and innovation. This enables the company to unlock more of the hidden potential of enzymes, microbes, and probiotics for animals, producers, and the entire value chain.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Codexis: Specialist protein engineering company using AI-driven directed evolution to design novel enzymes for pharmaceuticals and industrial biotech. Competes at the technology layer and is a potential disruptor in high-value enzyme niches.

Broad incumbents

• Kerry Group: Taste and nutrition company serving food and beverage customers with enzymes, cultures, and functional ingredients. Overlaps with Novonesis's food & beverage segment and competes for the same CPG customer wallets.
• BASF: Diversified chemical giant with an enzymes and biosolutions portfolio serving food, feed, and industrial customers. Competes with Novonesis as part of a much broader chemistry offering rather than a focused biosolutions strategy.

Direct peers

• AB Enzymes (Associated British Foods): Specialist industrial enzyme manufacturer serving baking, beverage, and animal feed markets. Direct competitor to Novonesis's enzyme portfolio, particularly in food processing and grain processing enzymes.
• Amano Enzyme: Japanese enzyme manufacturer producing industrial, food, and diagnostic enzymes. Direct competitor in food and beverage enzymes with strong presence in Asia-Pacific, complementing Novonesis's regional footprint.
• Lesaffre: Global yeast and fermentation products company with growing presence in probiotics and bioactives. Comparable fermentation expertise and overlap in baking, food, and human/animal nutrition probiotics.
• International Flavors & Fragrants (IFF): IFF merged with DuPont's Nutrition & Biosciences division, creating the largest direct competitor to Novonesis in enzymes, cultures, and food/feed biosolutions. Highly comparable across industrial enzymes, probiotics, and food ingredients.
• Lallemand: Private Canadian yeast, bacteria, and probiotic producer serving baking, animal nutrition, and human health. Direct competitor in microbial solutions and probiotics with comparable go-to-market in food and animal health.
• dsm-firmenich: Global nutrition, health, and biosciences company with overlapping capabilities in animal nutrition enzymes, vitamins, and flavors. Former Feed Enzyme Alliance partner of Novozymes; competes in human and animal nutrition.

Others

• Chr. Hansen (now part of Novonesis): Historical direct peer in probiotics and microbial solutions; now merged into Novonesis. Pre-merger it was a comparable biosolutions platform and remains a useful benchmark for understanding Novonesis's combined product mix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Novozymes
• YouTubeyoutube.com/@Novonesis
• Facebookfacebook.com/Novozymes
• LinkedInlinkedin.com/company/novozymes
• Instagraminstagram.com/novonesis

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A16 records

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novozymes